Avidity Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avidity Biosciences (NASDAQ: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three upcoming investor conferences in September 2025.

The management team will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley Global Healthcare Conference on September 8. Live webcasts and replays will be available on the company's investor relations website.

SAN DIEGO, Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conferences:

• Cantor Global Healthcare Conference 2025 – New York, NY
  Wednesday, September 3, 2025, at 7:20 a.m. PT | 10:20 a.m. ET
• 2025 Wells Fargo Healthcare Conference – Everett, MA
  Thursday, September 4, 2025, at 9:45 a.m. PT | 12:45 p.m. ET
• Morgan Stanley 23rd Annual Global Healthcare Conference – New York, NY
  Monday, September 8, 2025, at 10:50 a.m. PT | 1:50 p.m. ET

Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity

Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302538395.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences (RNA) presenting at the Cantor Global Healthcare Conference 2025?

Avidity Biosciences will present at the Cantor Global Healthcare Conference on Wednesday, September 3, 2025, at 7:20 a.m. PT / 10:20 a.m. ET in New York, NY.

What type of events will Avidity Biosciences (RNA) participate in at these healthcare conferences?

Avidity Biosciences management will participate in fireside chat discussions at all three conferences.

Where can investors watch Avidity Biosciences' (RNA) conference presentations?

Investors can access live webcasts and archived replays of the presentations on Avidity's website at aviditybiosciences.investorroom.com/events-and-presentations.

What is Avidity Biosciences' (RNA) main focus as a company?

Avidity Biosciences is a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).